210 related articles for article (PubMed ID: 29284789)
21. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways.
Jin HY; Oda H; Lai M; Skalsky RL; Bethel K; Shepherd J; Kang SG; Liu WH; Sabouri-Ghomi M; Cullen BR; Rajewsky K; Xiao C
EMBO J; 2013 Aug; 32(17):2377-91. PubMed ID: 23921550
[TBL] [Abstract][Full Text] [Related]
23. The miR-17∼92 microRNA Cluster Is a Global Regulator of Tumor Metabolism.
Izreig S; Samborska B; Johnson RM; Sergushichev A; Ma EH; Lussier C; Loginicheva E; Donayo AO; Poffenberger MC; Sagan SM; Vincent EE; Artyomov MN; Duchaine TF; Jones RG
Cell Rep; 2016 Aug; 16(7):1915-28. PubMed ID: 27498867
[TBL] [Abstract][Full Text] [Related]
24. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
25. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.
Calado DP; Sasaki Y; Godinho SA; Pellerin A; Köchert K; Sleckman BP; de Alborán IM; Janz M; Rodig S; Rajewsky K
Nat Immunol; 2012 Nov; 13(11):1092-100. PubMed ID: 23001146
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
27. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
[TBL] [Abstract][Full Text] [Related]
28. Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.
van Hamburg JP; de Bruijn MJ; Dingjan GM; Beverloo HB; Diepstraten H; Ling KW; Hendriks RW
Mol Immunol; 2008 Jun; 45(11):3085-95. PubMed ID: 18471881
[TBL] [Abstract][Full Text] [Related]
29. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
[TBL] [Abstract][Full Text] [Related]
30. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
31. Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation.
Burger ML; Xue L; Sun Y; Kang C; Winoto A
Blood; 2014 Jun; 123(26):4089-100. PubMed ID: 24735967
[TBL] [Abstract][Full Text] [Related]
32. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development.
Tagawa H; Karube K; Tsuzuki S; Ohshima K; Seto M
Cancer Sci; 2007 Sep; 98(9):1482-90. PubMed ID: 17608773
[TBL] [Abstract][Full Text] [Related]
33. Cooperative STAT/NF-κB signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression.
Feist M; Schwarzfischer P; Heinrich P; Sun X; Kemper J; von Bonin F; Perez-Rubio P; Taruttis F; Rehberg T; Dettmer K; Gronwald W; Reinders J; Engelmann JC; Dudek J; Klapper W; Trümper L; Spang R; Oefner PJ; Kube D
Nat Commun; 2018 Apr; 9(1):1514. PubMed ID: 29666362
[TBL] [Abstract][Full Text] [Related]
34. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
35. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
[TBL] [Abstract][Full Text] [Related]
36. miR-16 induction after CDK4 knockdown is mediated by c-Myc suppression and inhibits cell growth as well as sensitizes nasopharyngeal carcinoma cells to chemotherapy.
Jiang Q; Zhang Y; Zhao M; Li Q; Chen R; Long X; Fang W; Liu Z
Tumour Biol; 2016 Feb; 37(2):2425-33. PubMed ID: 26383521
[TBL] [Abstract][Full Text] [Related]
37. MicroRNAs as regulators and mediators of c-MYC function.
Jackstadt R; Hermeking H
Biochim Biophys Acta; 2015 May; 1849(5):544-53. PubMed ID: 24727092
[TBL] [Abstract][Full Text] [Related]
38. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level.
Wang Z; Liu M; Zhu H; Zhang W; He S; Hu C; Quan L; Bai J; Xu N
Int J Oncol; 2010 Nov; 37(5):1315-21. PubMed ID: 20878079
[TBL] [Abstract][Full Text] [Related]
39. Widespread microRNA repression by Myc contributes to tumorigenesis.
Chang TC; Yu D; Lee YS; Wentzel EA; Arking DE; West KM; Dang CV; Thomas-Tikhonenko A; Mendell JT
Nat Genet; 2008 Jan; 40(1):43-50. PubMed ID: 18066065
[TBL] [Abstract][Full Text] [Related]
40. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.
Sabò A; Kress TR; Pelizzola M; de Pretis S; Gorski MM; Tesi A; Morelli MJ; Bora P; Doni M; Verrecchia A; Tonelli C; Fagà G; Bianchi V; Ronchi A; Low D; Müller H; Guccione E; Campaner S; Amati B
Nature; 2014 Jul; 511(7510):488-492. PubMed ID: 25043028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
